Cyril Amarchand Mangaldas advised Organon & Co. on its acquisition by Sun Pharmaceutical Holdings USA, Inc.
The leading law firm in India, Cyril Amarchand Mangaldas advised Organon & Co. (NYSE: OGN) on its acquisition by Sun Pharmaceutical Holdings USA, Inc., April 27, 2026, Mumbai.
The transaction involves the acquisition of Organon & Co., a global healthcare company with a diverse portfolio spanning women’s health, biosimilars, and therapies for a wide range of conditions and diseases, by Sun Pharmaceutical Holdings USA, Inc., a U.S. subsidiary of Sun Pharmaceutical Industries Ltd (NSE: SUNPHARMA), one of India’s leading pharmaceutical companies and among the largest specialty generic pharmaceutical companies globally.
The completion of the transaction is subject to customary regulatory approvals and closing conditions.
The Cyril Amarchand Mangaldas team was led by Ruetveij Pandya (Partner) and Saloni Shroff (Partner), with support from Abhilasha Malpani (Principal Associate), Sajith Anjickal (Associate), Chelsea Sawlani (Associate), Neelanshi Gupta (Associate), Simran Srivastava (Associate), and Shravan Subramanian (Associate).
Rishabh Shroff (Partner, Co-Head – Private Client and Head – International Business Development) provided strategic inputs and guidance, while on financing aspects of the transaction, the team was led by Meeta Kurpad (Partner), supported by Manasvin Andra (Associate).
Click to know more about Cyril Amarchand Mangaldas
If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at [email protected] or call us on +91 8879634922.